Skip to main content

Research Repository

Advanced Search

Measuring the impact of steroid therapy on health-related quality of life in patients with rheumatic diseases: International development of a glucocorticoid treatment-specific patient-reported outcome measure

Bridgewater, Susan; Shepherd, Michael A.; Dawson, Jill; Richards, Pamela; Silverthorne, Christine; Ndosi, Mwidimi; Almeida, Celia; Black, Rachel J.; Cheah, Jonathan T.L.; Dures, Emma; Ghosh, Nilasha; Hoon, Elizabeth A.; Lyne, Suellen; Navarro-Millan, Iris; Pearce-Fisher, Diyu; Ruediger, Carlee; Tieu, Joanna; Yip, Kevin; Mackie, Sarah L.; Goodman, Susan; Hill, Catherine; Robson, Joanna C.

Measuring the impact of steroid therapy on health-related quality of life in patients with rheumatic diseases: International development of a glucocorticoid treatment-specific patient-reported outcome measure Thumbnail


Authors

Michael A. Shepherd

Jill Dawson

Pamela Richards

Profile image of Mwidimi Ndosi

Dr Mwidimi Ndosi Mwidimi.Ndosi@uwe.ac.uk
Associate Professor in Nursing Rheumatology

Rachel J. Black

Jonathan T.L. Cheah

Emma Dures Emma2.Dures@uwe.ac.uk
Professor in Rheumatology and Self-management

Nilasha Ghosh

Elizabeth A. Hoon

Suellen Lyne

Iris Navarro-Millan

Diyu Pearce-Fisher

Carlee Ruediger

Joanna Tieu

Kevin Yip

Sarah L. Mackie

Susan Goodman

Catherine Hill

Jo Robson Jo.Robson@uwe.ac.uk
Consultant Associate Professor in Rheumatology



Abstract

OBJECTIVES: Glucocorticoids (GCs) ('steroids') are used to treat rheumatic diseases but adverse effects are common. We aimed to explore the impact of GC therapy on health-related quality of life (HRQoL), to inform the development of a treatment-specific patient-reported outcome measure (PROM) for use in clinical trials and practice. METHODS: Semi-structured qualitative interviews were conducted with patients from the UK, USA and Australia, treated for a rheumatic condition with GCs in the last 2 years. Purposive sampling was used to select participants with a range of demographic and disease features. An initial conceptual framework informed interview prompts and cues. Interviews elicited GC-related physical and psychological symptoms and salient aspects of HRQoL in relation to GC therapy. Interview data were analysed inductively to develop initial individual themes and domains. Candidate questionnaire items were developed and refined. RESULTS: Sixty semi-structured qualitative interviews were conducted (UK n = 34, USA n = 10, Australia n = 16). The mean age was 58 years; 39/60 were female; and 18 rheumatic diseases were represented. Some 126 individual themes were identified and organized into six domains: physical symptoms; psychological symptoms; psychological impact of steroids; impact of steroids on participation; impact of steroids on relationships; and benefits of steroids. Candidate questionnaire items were tested and refined by piloting with patient research partners, iterative rounds of cognitive interviews and linguistic translatability assessment, informing a draft questionnaire. CONCLUSION: We describe an international qualitative study to develop candidate items for a treatment-specific PROM for patients with rheumatic diseases. A future survey will enable the validation of a final version of the PROM.

Journal Article Type Article
Acceptance Date Feb 15, 2023
Online Publication Date Feb 25, 2023
Publication Date Nov 30, 2023
Deposit Date Mar 1, 2023
Publicly Available Date Nov 3, 2023
Journal Rheumatology
Print ISSN 1462-0324
Electronic ISSN 1462-0332
Publisher Oxford University Press (OUP)
Peer Reviewed Peer Reviewed
Volume 62
Issue 11
Pages 3565–3575
DOI https://doi.org/10.1093/rheumatology/kead081
Keywords rheumatic diseases, glucocorticoid steroids, quality of life, patient reported outcomes
Public URL https://uwe-repository.worktribe.com/output/10487388
Publisher URL https://academic.oup.com/rheumatology/advance-article-abstract/doi/10.1093/rheumatology/kead081/7058129?redirectedFrom=fulltext&login=false

Files





You might also like



Downloadable Citations